HDAC9 and acute myeloid leukemia: To exclude the WS6 off-target effect, we demonstrated that WS6 lacks activity against HDAC in biological assays, as shown by the comparative quantification of H3K27 acetylation and β-tubulin in EVI1High-treated AML cell lines (Supplementary Fig. 11C).